Literature DB >> 33285392

Socio-ecological and pharmacy-level factors associated with naloxone stocking at standing-order naloxone pharmacies in New York City.

Bilal Abbas1, Phillip L Marotta2, Dawn Goddard-Eckrich1, Diane Huang1, Jakob Schnaidt1, Nabila El-Bassel1, Louisa Gilbert1.   

Abstract

BACKGROUND: Research on socio-ecological factors that may impede or facilitate access to naloxone in pharmacies remains limited. This study investigated associations between socio-ecological factors, pharmacy participation in the naloxone cost assistance program (NCAP), pharmacy characteristics and having naloxone in stock among pharmacies in New York City.
METHODS: Phone interviews were conducted with 662 pharmacies selected from the New York City Naloxone Standing Order List. Multi-level generalized linear modeling estimated associations between neighborhood racial and ethnic composition, poverty rates, overdose fatality rates, pharmacy participation in N-CAP, having private physical spaces within the pharmacy, knowledge of where to refer people to obtain naloxone and adjusted relative risk (aRR) that the pharmacy would have naloxone in stock.
RESULTS: Findings from this study supported several of the hypotheses. Greater neighborhood poverty was associated with a lower likelihood of carrying naloxone compared to neighborhoods with less poverty (aRR = .79, CI95 % = .69, .90, p < .001). Pharmacies that provided a private window for consultations (aRR = 1.34, CI95 % = 1.19, 1.51, p < .001), a private room (aRR = 1.42, CI95 % = 1.30, 1.56, p < .001), and a private area (aRR = 1.42, CI95 % = 1.30, 1.56, p < .001) were associated with a higher likelihood of carrying naloxone compared than those that did not.
CONCLUSIONS: Findings from this study suggest that community-level socioeconomic marginalization is a contributor to disparities in naloxone availability among pharmacies in New York City. Findings support harm reduction interventions tailored to the built environment of pharmacies that respect privacy to those seeking naloxone.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Harm reduction; Naloxone; Neighborhoods; Overdose; Pharmacy; Socioeconomic disparity

Year:  2020        PMID: 33285392     DOI: 10.1016/j.drugalcdep.2020.108388

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  4 in total

1.  Limited access to pharmacy-based naloxone in West Virginia: Results from a statewide purchase trial.

Authors:  Robin A Pollini; Jenny E Ozga; Rebecca Joyce; Ziming Xuan; Alexander Y Walley
Journal:  Drug Alcohol Depend       Date:  2021-12-31       Impact factor: 4.492

2.  Evaluating disparities in prescribing of naloxone after emergency department treatment of opioid overdose.

Authors:  Scott G Weiner; Aleta D Carroll; Nicholas M Brisbon; Claudia P Rodriguez; Charles Covahey; Erin J Stringfellow; Catherine DiGennaro; Mohammad S Jalali; Sarah E Wakeman
Journal:  J Subst Abuse Treat       Date:  2022-04-30

3.  Community-based naloxone coverage equity for the prevention of opioid overdose fatalities in racial/ethnic minority communities in Massachusetts and Rhode Island.

Authors:  Shayla Nolen; Xiao Zang; Avik Chatterjee; Czarina N Behrends; Traci C Green; Aranshi Kumar; Benjamin P Linas; Jake R Morgan; Sean M Murphy; Alexander Y Walley; Shapei Yan; Bruce R Schackman; Brandon D L Marshall
Journal:  Addiction       Date:  2021-12-05       Impact factor: 7.256

4.  Preventing Overdose Using Information and Data from the Environment (PROVIDENT): protocol for a randomized, population-based, community intervention trial.

Authors:  Brandon D L Marshall; Nicole Alexander-Scott; Jesse L Yedinak; Benjamin D Hallowell; William C Goedel; Bennett Allen; Robert C Schell; Yu Li; Maxwell S Krieger; Claire Pratty; Jennifer Ahern; Daniel B Neill; Magdalena Cerdá
Journal:  Addiction       Date:  2021-11-29       Impact factor: 6.526

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.